Aerpio Pharmaceuticals, Inc. (Nasdaq:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that Chief Executive Officer, Stephen Hoffman, M.D., Ph.D., will present at the Cantor Fitzgerald 2018 Global Healthcare Conference on Monday, October 1, 2018 at 10:40 a.m. Eastern Time in New York, NY. Dr. Hoffman will provide a corporate overview and business update.
The presentation will be webcast live and may be accessed by visiting Aerpio's website at http://ir.aerpio.com/.
About Aerpio Pharmaceuticals
Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases. The Company’s lead compound, AKB-9778, is a small molecule activator of the Tie2 pathway and is in clinical development for the treatment of non-proliferative diabetic retinopathy. For more information, please visit www.aerpio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180924005069/en/
Contacts:
Aerpio
Pharmaceuticals, Inc.
Michael Rogers
Chief Financial
Officer
mrogers@aerpio.com
or
Burns
McClellan, on behalf of Aerpio Pharmaceuticals, Inc.
Media:
Robert
Flamm, Ph.D.
rflamm@burnsmc.com
or
Investors:
Ami
Bavishi
abavishi@burnsmc.com
